CPT1A and metabolic dysfunction-associated steatotic liver disease: Despite the lack of direct evidence that GA upregulates FAO-related enzymes in the kidney, studies using a hepatocellular model of non-alcoholic fatty liver disease (NAFLD) have shown that GA increases the expression of FAO-related genes, such as PPARα and CPT1A, thereby reducing hepatic steatosis (110).